Search Results 101-110 of 16605 for Certolizumab

1. Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such ...

2. Typhoid vaccine, live (oral route) - Mayo Clinic

   Belatacept; Betibeglogene Autotemcel; Bimekizumab-bkzx; Brodalumab; Canakinumab; Certolizumab Pegol; Cyclosporine; Deucravacitinib; Deuruxolitinib; Dupilumab ...

3. Infliximab-qbtx (intravenous route) - Side effects & uses - Mayo Clinic

   Certolizumab Pegol; Cholera Vaccine, Live; Cyclosporine; Dengue Tetravalent Vaccine, Live; Ebola Zaire Vaccine, Live; Etanercept; Fosphenytoin; Golimumab ...

4. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

   This is a combination Phase I and Phase II study, with an aim to evaluate the combination of GSK525762 and fulvestrant in women with advanced or metastatic ER+ ...

5. TD-1473 for Active Ulcerative Colitis (UC) - Mayo Clinic

   ... certolizumab within the 60 days prior to Day 1, c) intravenous corticosteroids within the 14 days prior to Day 1, d) topical mesalamine or steroid (i.e. ...

6. A Study to Evaluate Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis - Mayo Clinic

   ... certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, tofacitinib, rituximab, or anakinra. Contraindications to contrast ...

7. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

   Certolizumab pegol: at least 14 weeks treatment at the approved doses for induction and/or maintenance in Crohn´s disease prior to screening for the study.

8. Measles, mumps, and rubella virus vaccine live (subcutaneous route, intramuscular route) - Side effects & uses - Mayo Clinic

   Baricitinib; Belatacept; Betibeglogene Autotemcel; Bimekizumab-bkzx; Brodalumab; Canakinumab; Certolizumab Pegol; Cyclosporine; Deucravacitinib; Deuruxolitinib ...

9. Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies - Mayo Clinic

   This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab ...

10. Tolerability, safety and deep response found in cevostamab phase 1 trial - Mayo Clinic

    A midterm analysis of a multisite phase 1 study of cevostamab for relapsed or refractory multiple myeloma (RRMM) finds the drug safe and tolerable with deep ...